Literature DB >> 6272633

Metronidazole metabolism in cultures of Entamoeba histolytica and Trichomonas vaginalis.

B B Beaulieu, M A McLafferty, R L Koch, P Goldman.   

Abstract

Acetamide forms from metronidazole in cultures of either Entamoeba histolytica or Trichomonas vaginalis as it does in cultures of bacteria which are susceptible to this drug. Under aerobic conditions, the formation of acetamide is more rapid in a strain of T. vaginalis which is more susceptible to metronidazole. Thus, it appears that the formation of acetamide may be associated with the microbiocidal action of metronidazole.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6272633      PMCID： PMC181711          DOI： 10.1128/AAC.20.3.410

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  The establishment of various trichomonads of animals and man in axenic cultures.

Authors:  L S DIAMOND
Journal:  J Parasitol       Date:  1957-08       Impact factor: 1.276

2.  Interaction of metronidazole with nucleic acids in vitro.

Authors:  N F LaRusso; M Tomasz; M Müller; R Lipman
Journal:  Mol Pharmacol       Date:  1977-09       Impact factor: 4.436

3.  Metronidazole ("Flagyl"). A radiosensitizer of hypoxic cells.

Authors:  J C Asquith; J L Foster; R L Willson; R Ings; J A McFadzean
Journal:  Br J Radiol       Date:  1974-08       Impact factor: 3.039

4.  The mode of action of metronidazole in Trichomonas vaginalis and other micro-organisms.

Authors:  R M Ings; J A McFadzean; W E Ormerod
Journal:  Biochem Pharmacol       Date:  1974-05-01       Impact factor: 5.858

5.  The anaerobic metabolism of metronidazole forms N-(2-hydroxyethyl)-oxamic acid.

Authors:  R L Koch; P Goldman
Journal:  J Pharmacol Exp Ther       Date:  1979-03       Impact factor: 4.030

6.  The interaction of reduced metronidazole with DNA.

Authors:  R C Knight; I M Skolimowski; D I Edwards
Journal:  Biochem Pharmacol       Date:  1978       Impact factor: 5.858

7.  Entamoeba histolytica. I. Aerobic metabolism.

Authors:  E C Weinbach; L S Diamond
Journal:  Exp Parasitol       Date:  1974-04       Impact factor: 2.011

8.  Uptake of metronidazole and its effect on viability in trichomonads and Entamoeba invadens under anaerobic and aerobic conditions.

Authors:  M Müller; D G Lindmark
Journal:  Antimicrob Agents Chemother       Date:  1976-04       Impact factor: 5.191

9.  Strain of Trichomonas vaginalis resistant to metronidazole and other 5-nitroimidazoles.

Authors:  J G Meingassner; J Thurner
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

10.  Metronidazole versus anaerobes. In vitro data and initial clinical observations.

Authors:  F P Tally; V L Sutter; S M Finegold
Journal:  Calif Med       Date:  1972-12
View more
  5 in total

1.  Viability of Trichomonas vaginalis in vitro at four temperatures.

Authors:  R F Smith
Journal:  J Clin Microbiol       Date:  1983-10       Impact factor: 5.948

2.  Metabolism and metronidazole uptake in Trichomonas vaginalis isolates with different metronidazole susceptibilities.

Authors:  M Müller; T E Gorrell
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

3.  Use of a time-kill technique for susceptibility testing of Trichomonas vaginalis.

Authors:  J N Krieger; C S Dickins; M F Rein
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

4.  Mechanism of toxicity of nitro compounds used in the chemotherapy of trichomoniasis.

Authors:  S N Moreno; R Docampo
Journal:  Environ Health Perspect       Date:  1985-12       Impact factor: 9.031

5.  PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release.

Authors:  Ramandeep Singh; Ujjini Manjunatha; Helena I M Boshoff; Young Hwan Ha; Pornwaratt Niyomrattanakit; Richard Ledwidge; Cynthia S Dowd; Ill Young Lee; Pilho Kim; Liang Zhang; Sunhee Kang; Thomas H Keller; Jan Jiricek; Clifton E Barry
Journal:  Science       Date:  2008-11-28       Impact factor: 63.714
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.